Liver X receptor alpha (LXRalpha) as a therapeutic target in chronic lymphocytic leukemia (CLL).
Christopherson
Kent W
KW
Landay
Alan
A
D002455:Cell Division / Q000187:drug effects; D015536:Down-Regulation; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000494:pharmacology / Q000627:therapeutic use; D007249:Inflammation / Q000235:genetics / Q000517:prevention & control; D007376:Interleukin-2 / Q000276:immunology; D015851:Interleukin-7 / Q000276:immunology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors / Q000819:agonists / Q000235:genetics / Q000502:physiology*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D005466:Fluorocarbons; D000096926:Benzenesulfonamides
D006845:Hydrocarbons, Fluorinated; D007376:Interleukin-2; D015851:Interleukin-7; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D013449:Sulfonamides; C000605213:NR1H3 protein, human; C423915:T0901317; D005466:Fluorocarbons; D000096926:Benzenesulfonamides